Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*

Background: An elevated level of low-density lipoprotein cholesterol (LDL-C) constitutes one of the most important modifiable risk factors for cardiovascular disease (CVD). Individuals with heterozygous familial hypercholesterolaemia (HeFH) are particularly vulnerable to CVD events. The addition of...

Full description

Bibliographic Details
Main Authors: Borislav Borissov, Michael Urbich, Boryana Georgieva, Svetoslav Tsenov, Guillermo Villa
Format: Article
Language:English
Published: Taylor & Francis Group 2017-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Cardiovascular diseases
hypercholesterolemia
cholesterol
lipoproteins
LDL
evolocumab
statin
cost-effectiveness
treatment outcome
quality of care
Bulgaria
Online Access:http://dx.doi.org/10.1080/20016689.2017.1412753

Internet

http://dx.doi.org/10.1080/20016689.2017.1412753

Similar Items